The treatment of renal lithiasis with biphosphonates;Tratamiento de la litiasis renal con bifosfonatos

Archivos Espanoles de Urologia

Volumn 60, Issue 7, 2007, Pages 745-754

  Martín, Miguel Arrabal ^a,b   De La Guardia, Francisco Valle Díaz ^a   Pacheco, Antonio Jiménez ^a   León, Víctor López ^a   Polo, Miguel Ángel Arrabal ^a   Gómez, Armando Zuluaga ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b Prof Agustín Escribano   (Spain)

Author keywords

Biphosphonates; Hypercalciuria; Renal lithiasis

Indexed keywords

ALENDRONIC ACID;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; MALE; MIDDLE AGED; NEPHROLITHIASIS;

ADULT; AGED; ALENDRONATE; FEMALE; HUMANS; KIDNEY CALCULI; MALE; MIDDLE AGED;

EID: 34648837001     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. FLEISCH, H.; RUSSELL, R.G.G.; BISAZ, S. y cols.: "The influence of phyrophosphatase analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo". Calcif. Tissue Res., 10: 15, 1968.
2. WATTS, N.B.: "Pharmacology of agents to treat osteoporosis. Bisphosphonates. Mechanism(s) of action". Favus, M.J. ed. Primer on the metabolic bone diseases ad disorders of mineral metabolism, pag. 278-83. Philadelphia, Lippincott Williams & Wilkins. 1999.
3. SRIVASTA, T.; ALON, U.S.: "Bisphosphonates: from grandparents to grandchildren". Clin. Pediatr., 38: 687, 1999.
4. ASTROM, E.; SODERHALL, S.: "Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta". Acta Paediatr., 87: 64, 1998.
5. LANE, J.M.; KHAN, S.N.; O'CONNOR, W.J. y cols.: "Bisphosphonate therapy in fibrous dysplasia". Clin. Orthop., 382: 6, 2001.
6. ADAMI, S.; FOSSALUZZA, V.; GATTI, D. y cols.: "Bisphosphonate therapy of reflex sympathetic dystrophy syndrome". Ann. Rheum. Dis., 56: 201, 1997.
7. BODY, J.J.; BARTI, R.; BURCKHARDT, P. y cols.: "Current use of bisphosphonates in Oncology". J. Clin. Oncol., 16: 3890, 1998.
8. PARKER, CR.; BLACKWELL, PJ.; FAIRBAIRN, K.J. y cols.: "Hosking-D-J. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study". J. Clin. Endocrinol. Metab., 87: 4482, 2002.
9. KARPF, D.B.; SHAPIRO, D.R.; SEEMAN, E. y cols.: "Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis treatment study groups". JAMA, 277: 1159, 1997.
10. BLACK, D.M.; CUMMINGS, S.R.; KARPF, D.B. y cols.: "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group". Lancet, 348: 1535, 1996.
11. RIZZOLI, R.; ROUX, C.; GRESPAN, S. y cols.: "Two year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis". Bone, 28: 94, 2001.
12. REGINSTER, J.; MINNE, H.W.; SORENSEN, O.H. y cols.: "Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group". Osteoporos. Int., 11: 83, 2000.
13. YENDT, E.R.; COHHANIM, M.: "Prevention of calcium stones with thiazides". Kidney Int., 13: 397, 1978.
14. LEMANN, J.R.; GRAY, R.W; MAIERHOFER, W.J. y cols.: " Hydrochllorothiazide inhibits bone resorption in men depite experimentally elevated serum 1, 25 dihydroxyvitamin D concentrations". Kidney Int., 28:951, 1985.
15. WEISINGER, J.R.; ALONZO, E.; MACHADO, C. y cols.: "Role of bones in the physiopathology of idiopathic hypercalciuria: effect of amino-bisphosphonate alendronate". Medicina (B. Aires). 1: 45, 1997.
16. JÓDAR JIMENO, E.; MARTÍNEZ DÍAZ-GUERRA, G.; HAWKINS CARRANZA, F.: "Efectos adversos y contraindicaciones de los bifosfonatos". Rapado Errazti, A. Díaz Curiel, M. editores. Bifosfonatos en las enfermedades del metabolismo óseo y mineral, pag. 113-22. FHOEMO. Madrid, 2002.
17. ARRABAL MARTÍN, M.; GUTIÉRREZ TEJERO, F.; ZULUAGA GÓMEZ, A.: "Síndrome hipercalcémico y enfermedades óseas. Litiasis urinaria". Lancina Martín, J.A. Arrabal Martín, M. Enfermedades sistémicas y litiasis urinaria, pag. 15-50. Editorial Visión Net. Madrid, 2004.
18. FUSS, M.; PEPERSACK, T.; VAN GEEL, J.: "Involvement of low-calcium diet in the reduced mineral content in idiopathic renal stone formers". Calcif. Tissue. Int., 46: 9, 1990.
19. HESS, B.; ACKERMAN, D.; ESSING, M. y cols.: "Renal mass and serum calcitriol in male idiopathic calcium renal stone formers: role of protein intake". J. Clin. Endocrinol. Metab., 80: 1916, 1995.
20. PACIFICI, R.; ROTHSTEIN, M.; RIFAS, L. y cols.: "Increased monocyte interleukin-1 activity and decreased vertebral bone density in patients with fasting idiopathic hypercalciuria". J. Clin. Endocrinol. Metab., 71: 138, 1990.
21. WEISENGER, J.R.; ALONZO, E.; BELLORIMFONT, E. y cols.: "Possible role of cytokines on the bone mineral loss in idiopathic hypercalciuria". Kidney Int., 49: 244, 1996.
22. HENRIQUEZ LA ROCHE.; RODRÍGUEZ ITURBE, B.; PARRA, G.: "Increased urinary excretion of PGE2 in patient with idiopathic hypercalciuria: the role of bone". Kidney Int., 49: 1507, 1996.
23. STEJMCHE, T.; MOSEKILDE, L.; CHRISTENSEN, M.S. y cols.: "A histomorphometric determination of iliac bone remodeling in patient with recurrent renal stone formation an idiopathic hypercalciuria". APMIS, 97: 309, 1989.
24. AUDRAN, M.; BATAILLE, P.; SEBERT, J.L. y cols.: "Bone density in idiopathic hypercalciuria in men. Study by dual photon absorptiometry, X-ray computed tomography and histomorphometry". Rev. Rhum. Mal. Osteoartic, 58: 747, 1991.
25. ZANCHETTA, J.R.; RODRIGUEZ, G.; NEGRI, A.L. y cols.: "Bone mineral density in patients with hypercalciuric nephrolithiasis". Nephron., 73: 557, 1996.
26. CAUDARELLA, R.; VESCINI, F.; BUFFA, A. y cols. "Bone mass loss in calcium stone disease: focus on hypercalciuria and metabolic factors". J. Nephrol., 16: 260, 2003.
27. GIANNINI, S.; NOBILE, M.; SELLA, S. y cols.: "Bone disease in primary hypercalciuria". Crit. Rev. Clin. Lab. Sci., 42: 229, 2005.
28. TSUJI, H.; UMEKAWA, T.; KURITA, T. y cols.: "Analysis of bone mineral density in urolithiasis patients". Int. J. Urol., 12: 335, 2005.
29. ARRABAL MARTÍN, M.; MIJÁN ORTIZ, J.L.; JIMÉNEZ VERDEJO, A. y cois.: "Hipofosfatemia, hipercalciuria y litiasis". LXIV Congreso Nacional de Urología. Zaragoza, 26 de mayo de 1999.
30. YAMAKAWA, K.; KAWAMURA, J.: "Analysis of hypophosphatemia in calcium nephrolithiasis". Mol. Urol., 4: 365, 2000.
31. FRIEDLANDER, G.: "Phosphate transport and kidney stones". Bull. Acad. Natl. Med., 189: 309, 2005.
32. CACHAT, F.; BARBEY, F.; DAUDON, M.: "Medical treatment of urinary lithiasis". Rev. Med. Suisse Romande., 124: 461, 2004.
33. FERNÁNDEZ, A.; ARRABAL, M.; GARCÍA, M.J. y cols.: "The role of thiazides in the prophylaxis of recurrent calcium lithiasis". Actas Urol. Esp., 30: 305, 2006.
34. PEARLE, M.S.; ROEHRBORN, C.G.; PAK, CY: "Meta-analysis of randimized trials for medical prevention of calcium oxalate nephrolithiasis". J. Endourol., 13: 679, 1999.
35. TISELIUS, H.G.: "Possibilities for preventing recurrent calcium stone formation: principles for the metabolic evaluation of patients with calcium stone disease". BJU Int., 88: 158, 2001.
36. ARRABAL, M.; FERNÁNDEZ, A.; ARRABALPOLO, M.A. y cols.: "Extracorporeal renal lithotripsy: evolution of residual lithiasis treated with thiazides". Urology, 68: 956, 2006.
37. SUAREZ FERNANDEZ, C.; RUILOPE URIOSTE, L.M.: "Thiazide diuretics and calcium metabolism: role in renal lithiasis and osteoporosis". An. Med. Interna, 13: 401, 1996.
38. LEGROUX-GEROT, I.; CATANZARITI, L.; MARCHANDISE, X. y cols.: "Bone mineral density changes in hypercalciuretic osteoporotic men treated with thiazide diuretics". Joint Bone Spine, 71: 51, 2004.
39. JACKSON, R.D.; LACROIX, A.Z.: "Calcium plus vitamin D supplementation and the risk of fractures". N. Engl. J. Med., 354: 669, 2006.
40. FLEISCH, H.: "Diphosphonates: history and mechanisms of action". Metab. Bone Dis. Relat. Res., 3: 279, 1981.
41. MEYTHALER, J.M.; TUEL, S.M.; CROSS, L.L.: "Successful treatment of immobilization hyper-calcemia using calcitonin and etidronate". Arch. Phys. Med. Rehabil., 74: 316, 1993.
42. SENZAKI, H.; YASUI, T.; OKADA, A. y cols.: "Alendronate inhibits urinary calcium microlith formation in a three-dimensional culture model". Urol. Res., 32: 223, 2004.
43. GUPTA, M.; TUNCAY, O.L.; VALDERRAMA, E. y cols.: "Inhibition of calcium oxalate urolithiasis in a rat model of lithogenesis using bisphosphonates". J. Endourol., 11: 1, 1997.
44. BUSHINSKY, D.A.; NEUMANN, K.J.; ASPLIN, J. y cols.: "Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats". Kidney Int., 55: 234, 1999.
45. RUML, L.A.; DUBOIS, S.K.; ROBERTS, M.L. y cols.: "Prevention of hypercalciuria and stoneforming propensity during prolonged bedrest by alendronate". J. Bone Miner. Res., 10: 655, 1995.
46. SKIDER, M.N.; ITOH, M.; IWATSUKI, N. y cols.: "Inhibitory effect of a novel bisphosphonate, TRK-530, on dental calculus formation in rats". J. Periodontol., 75: 537, 2004.
47. VAN DYCK, M.; PROESMANS, W.; VAN HOLLEBEKE, E. y cols.: "Idiopathic infantile arterial calcification with cardiac, renal and central nervous system involvement". Eur. J. Pediatr., 148: 374, 1989.
48. MCCREDIE, D.A.; POWELL, H.R.; ROTENBERG, E.: "Diphosphonate therapy in nephrocalcinosis". Br. J. Urol., 48: 93, 1976.
49. BONE, H.G.; ZERWEKH, J.E.; BRITTON, F. y cols.: "Treatment of calcium urolithiasis with diphosphonate: efficacy and hazards". J. Urol., 121: 568, 1979.
50. VAIDYANATHAN, S.; WATSON, I.D.; JONSSON, O. y cols.: "Recurrent vesical calculi, hypercalciuria, and biochemical evidence of increased bone resorption in an adult male with paraplegia due to spinal cord injury: is there a role for intermittent oral disodium etidronate therapy for prevention of calcium phosphate bladder stones". Spinal Cord., 43: 269, 2005.
51. HEILBERG, L.P.; MARTINI, L.A.; TEIXEIRA, S.H. y cols.: "Effect of etidronate treatment on bone mass of male nephrolithiasis patients with idiopathic hypercalciuria and osteopenia". Nephron., 79: 430, 1998.
52. WATANABE, Y.; OHSHIMA, H.; MIZUNO, K. y cols.: "Intravenous Pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest." J. Bone Miner. Res., 19: 1771, 2004.